Your browser doesn't support javascript.
loading
The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus.
Eudy, Amanda M; Clowse, Megan Eb; Corneli, Amy; McKenna, Kevin; Pisetsky, David S; Maheswaranathan, Mithu; Burshell, Dana; Doss, Jayanth; Sun, Kai; Sadun, Rebecca E; Criscione-Schreiber, Lisa G; Rogers, Jennifer L.
Afiliação
  • Eudy AM; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Clowse ME; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Corneli A; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • McKenna K; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
  • Pisetsky DS; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
  • Maheswaranathan M; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Burshell D; Durham VA Medical Center, Durham, NC, USA.
  • Doss J; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Sun K; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Sadun RE; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Criscione-Schreiber LG; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Rogers JL; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Lupus ; 33(3): 266-272, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38238905
ABSTRACT

OBJECTIVE:

In the new Type 1 & 2 model for systemic lupus erythematosus (SLE), Type 1 SLE represents classic inflammatory manifestations, such as arthritis, while Type 2 SLE encompasses symptoms such as pain and fatigue where the relationship to inflammation is less clear. The objective of this study was to interview individuals living with SLE to determine the content and face validity of the Type 1 & 2 SLE model.

METHODS:

We conducted a qualitative study using semi-structured interviews with a purposeful sample of participants who met classification criteria for SLE. Participants were asked to describe their experiences with Type 1 & 2 SLE symptoms and treatments, and they indicated if and how their personal experiences aligned with the Type 1 & 2 SLE model. All interviews were audio-recorded and transcribed; applied thematic analysis identified the most frequent and salient themes.

RESULTS:

We interviewed 42 participants with SLE. Type 2 SLE symptoms, such as pain and fatigue, were very common, with almost all participants experiencing some Type 2 symptoms at some point during their disease course. Participants described Type 1 SLE symptoms as being acute flares and life-threatening and Type 2 SLE symptoms as "everyday lupus" that affected their daily lives and were a dominant part of their SLE disease experience. Most participants stated they want their rheumatologists to discuss Type 2 symptoms during clinical appointments in order to address their full symptom experience.

CONCLUSION:

We demonstrated content and face validity of the Type 1 & 2 SLE model with people living with SLE. Participants in our study largely understood the model and felt it accurately reflected their experience living with SLE. Type 2 SLE symptoms are very common in individuals with SLE and impact patients' quality of life. Using the model to address Type 2 SLE symptoms allows the rheumatologist to incorporate the patient's perspective and provide patient-centered care.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite / Lúpus Eritematoso Sistêmico Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite / Lúpus Eritematoso Sistêmico Idioma: En Ano de publicação: 2024 Tipo de documento: Article